Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

NCT01644396 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT01644396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01644396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2012
Completion date
September 30, 2013
Enrollment
50 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe plaque psoriasis